A disease prevention approach that involves targeting the molecular antecedents of disease, such as molecular antecedents for cancer
If a nutrient has beneficial effects at doses much higher than needed for the prevention of deficiency, how should this affect the setting of EARs and RDAs?
If a nutrient prevents an adverse outcome in one subgroup but not in another, how can this information be incorporated into a DRI process?
Should the concept of a range of nutrient intake be reconsidered, or is there some other method to incorporate information about disease prevention (including subgroup-specific information) into the DRI process?
Development of a standard approach for setting an AI
Should an Adequate Intake (AI) be set for a nutrient that has no known essential functions in humans?
Can the process of setting ULs be made more systematic—one that consistently uses a decision tree approach?
Could risk assessment methodology be used to evaluate the lower end rather than just the upper end of nutrient risk?
New concerns for ULs related to epigenetic effects and genetic rescue
Can the UL concept be expanded to include a numerical value for nutrients for which an adverse effect or a toxicity has not been clearly established?
Are separate UL values needed for different forms of a nutrient?
Methods to apply the DRI process to chronic diseases
The meaning of “healthy population” in relation to setting DRIs
Setting ULs for nutrients for which there is a direct progressive relationship between intake and occurrence and/or severity of the adverse effect but for which there is no threshold
Criteria and methods for adjusting nutrient recommendations, as for age, size
A basis for expressing DRIs as densities or ratios
Consumer communication research